Ceftriaxone

제한된
0
C. difficile 위험도
High
경구생체이용률
N/A

Dosing

Usual doseBacterial meningitisMSSA infection1-2 g IV #1-22 g IV q12h (max 4 g/d)2-4 g IV #1-2No renal dose adjustment

SSTISevere non-CNS infectionBacterial meningitis50-75 mg/kg IV #1-2 (max 2 g/d)50-75 mg/kg IV #2 (max 2 g/d)100 mg/kg IV #1-2 (max 4 g/d)No renal dose adjustment

No dose adjustment

General Information

Empiric therapy of:

  • Bacterial meningitis

  • Nosocomial gram negative infections (except Pseudomonas)

  • Spontaneous bacterial peritonitis

  • Hospitalized community or nursing home-acquired pneumonia in combination with a macrolide

Monitor CBC, hepatic and renal functions, previous hypersensitivity to other beta-lactam antibiotics, and signs of antibiotic-associated diarrhea and other superinfections.

Common

  • Diarrhea

  • Eosinophilia

  • Thrombocytosis

  • Injection site induration

Serious

  • Erythema multiforme

  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Clostridium difficile colitis

  • Injury of lung

  • Renal failure

  • Hypersensitivity reaction

  • Hemolytic anemia

  • Kernicterus (newborn)

Contraindications:

  • Ringer's solution

  • Lactated Ringer's solution

  • Calcium-containing IV solutions

Major drug-drug interactions:

  • Cholera vaccine, live

Antimicrobial class: 3rd Generation Parenteral Cephalosporin

Pregnancy category: B

Average serum half life: 8 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Precautions:

  • Do not concurrently administer calcium-containing IV solutions in same IV line, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site; may be administered sequentially in patients other than neonates with thorough flushing of lines with compatible fluid between administrations.

  • Increased risk of drug toxicity in renal failure.

  • Use caution in patients with impaired vitamin K synthesis or low vitamin K stores due to risk of rare prothrombin time alteration.

  • Discontinue if hemolytic anemia occurs.

  • Use caution in patients with history of allergy.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.